多西他赛+卡培他滨治疗Her2阴性复发转移乳腺癌的临床效果分析

Clinical EffectAnalysis of Docetaxel Combined with Capecitabine in the Treatment of Her2-negative Recurrent Metastatic Breast Cancer

目的分析多西他赛联合卡培他滨治疗Her2阴性复发转移乳腺癌的临床效果。方法选取2015年1月~2019年12月我院收治的Her2阴性复发转移性乳腺癌患者60例,随机数字表法分为观察组和对照组各30例。对照组予卡培他滨治疗,观察组予卡培他滨联合多西他赛治疗,对比两组近期疗效、远期疗效、毒副反应、血清癌胚抗原(CEA)、癌抗原19-9(CA19-9)水平。结果观察组疾病控制率为73.33%,高于对照组的46.67%,治疗有效率为93.33%,高于对照组的70.00%,差异均有统计学意义(P<0.05)。观察组总生存期、无进展生存期均长于对照组,差异均有统计学意义(P<0.05)。两组血小板减少、手足综合征、WBC减少、脱发、恶心呕吐等毒副反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组血清CA19-9、CEA水平比较,差异无统计学意义(P>0.05);治疗后,观察组CA19-9、CEA水平均低于对照组,差异均有统计学意义(P<0.05)。结论多西他赛与卡培他滨联合治疗Her2阴性复发转移乳腺癌可有效降低患者血清CA19-9、CEA水平,未加重不良反应,安全性尚可,近远期疗效好,值得临床推广。

Objective To analyze the clinical effects of docetaxel combined with capecitabine in the treatment of recurrent metastatic breast cancer.Methods 60 patients with Her2-negative recurrent metastatic breast cancer admitted to our hospital from January 2015 to December 2019 were selected and divided into observation group and control grouprandomly.The 30 cases in control group were treated with capecitabine,whereas the 30 cases in observation groupwere treated with docetaxel combined with capecitabine.The short-term efficacy,long-term efficacy,toxicity,serum carcinoembryonic antigen(CEA)and carcer antigen 19-9(CA19-9)levels were compared between the two groups.Results For the observation group,the disease control rate and treatment efficiencyare 73.33%and 93.33%,respectively,both significantly greater than the 46.67%and 70.00%in the control group(P<0.05).The overall survival and progression-free survival are surpass that of the observation group(P<0.05).There was no significant difference in the incidence of adverse reactions such as thrombocytopenia,hand and foot syndrome,leucopenia,alopecia,nausea and vomitingbetween the two groups(P>0.05).There was no difference in serum CA19-9 and CEA between the two groups before treatment(P>0.05),yetthey were significantly lower in the observation group after the treatment(P<0.05).Conclusion TreatingHer-negative recurrent metastatic breast cancer with docetaxel combined with capecitabine can effectively reduce the Serum CA19-9 and CEA levels,and both short-term and long-term effect are satisfying.Additionally,the therapy is relatively safe while not aggravating the adverse reactions,which is worthy of clinical promotion.